Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Charter Communications
CHTR
|
+$601M |
| 2 |
Parker-Hannifin
PH
|
+$576M |
| 3 |
JPMorgan Chase
JPM
|
+$575M |
| 4 |
Goldman Sachs
GS
|
+$452M |
| 5 |
FedEx
FDX
|
+$371M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$733M |
| 2 |
American Tower
AMT
|
+$684M |
| 3 |
Nike
NKE
|
+$601M |
| 4 |
AGN
Allergan plc
AGN
|
+$561M |
| 5 |
McDonald's
MCD
|
+$536M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.7% |
| 2 | Consumer Discretionary | 17.46% |
| 3 | Healthcare | 13.37% |
| 4 | Communication Services | 12.12% |
| 5 | Financials | 11.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Agnico Eagle Mines
AEM
$71.9B
| $40.1M | 0.04% |
955,692
-68,870
| -7% | -$3.04M |
|
302
Thermo Fisher Scientific
TMO
$214B
| $40M | 0.04% |
283,314
-6,388
| -2% | -$942K |
|
|
THS
303
DELISTED
Treehouse Foods
THS
| $39.8M | 0.04% |
+551,109
| New | +$42.1M |
|
304
Acadia Pharmaceuticals
ACAD
$4.45B
| $39.6M | 0.04% |
+1,372,679
| New | +$36.3M |
|
305
Benchmark Electronics
BHE
$2.76B
| $39.5M | 0.04% |
1,296,645
+65,636
| +5% | +$1.8M |
|
|
GNMK
306
DELISTED
GenMark Diagnostics, Inc
GNMK
| $39.4M | 0.04% |
3,222,716
+342,213
| +12% | +$4.06M |
|
307
Devon Energy
DVN
$49.2B
| $39.2M | 0.04% |
859,236
-316,596
| -27% | -$14M |
|
308
Boston Scientific
BSX
$68.5B
| $38.7M | 0.04% |
+1,788,316
| New | +$39M |
|
|
DBD
309
DELISTED
Diebold Nixdorf Incorporated
DBD
| $38.5M | 0.04% |
1,532,529
-460,740
| -23% | -$10.9M |
|
|
NFX
310
DELISTED
Newfield Exploration
NFX
| $38.3M | 0.04% |
945,926
-1,233,825
| -57% | -$52.4M |
|
311
General Dynamics
GD
$106B
| $38.1M | 0.04% |
220,606
+198,950
| +919% | +$32.5M |
|
312
Darling Ingredients
DAR
$9.28B
| $38M | 0.04% |
2,947,187
+74,373
| +3% | +$1.01M |
|
|
VWR
313
DELISTED
VWR Corporation
VWR
| $37.3M | 0.04% |
1,489,896
+457,622
| +44% | +$12.2M |
|
|
BMS
314
DELISTED
Bemis
BMS
| $37.2M | 0.04% |
778,915
-419,436
| -35% | -$20.7M |
|
315
Target
TGT
$65.5B
| $37.1M | 0.04% |
514,104
-48,458
| -9% | -$3.51M |
|
|
BRCD
316
DELISTED
Brocade Communications Systems, Inc. NEW
BRCD
| $36.6M | 0.04% |
2,927,443
-3,080,175
| -51% | -$34.7M |
|
317
Criteo
CRTO
$1.06B
| $36.2M | 0.04% |
880,233
+22,038
| +3% | +$859K |
|
|
DNKN
318
DELISTED
Dunkin' Brands Group, Inc.
DNKN
| $36.1M | 0.04% |
688,024
+167,030
| +32% | +$8.6M |
|
319
Texas Roadhouse
TXRH
$13.5B
| $35.8M | 0.04% |
742,841
-20,392
| -3% | -$897K |
|
320
CoreCivic
CXW
$3.03B
| $35.5M | 0.04% |
+1,451,263
| New | +$27.7M |
|
321
Ultragenyx Pharmaceutical
RARE
$2.56B
| $35.2M | 0.04% |
500,290
+1,844
| +0.4% | +$131K |
|
322
Honeywell
HON
$78.3B
| $35.1M | 0.04% |
335,161
+326,312
| +3,688% | +$33.2M |
|
|
NXTM
323
DELISTED
NxStage Medical Inc.
NXTM
| $34.8M | 0.04% |
1,328,173
+21,686
| +2% | +$536K |
|
324
Owens Corning
OC
$11.5B
| $34.7M | 0.04% |
672,913
-275,926
| -29% | -$14.3M |
|
325
Southern Copper
SCCO
$140B
| $34.5M | 0.04% |
1,163,610
-79,086
| -6% | -$2.23M |
|
Similar funds
Jennison Associates's Q4 2016 Portfolio in Review
As of Q4 2016, Jennison Associates held 857 positions worth $89.6B, down 3.4% from $92.8B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Jennison Associates withdrew a net $3.76B in Q4 2016, closing 52 positions and reducing 313 holdings. Its most notable exit was lululemon athletica, an estimated $342M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jennison Associates opened a new position in Parker-Hannifin worth $606M.
- Jennison Associates's largest Q4 2016 buy was Parker-Hannifin: 4,330,276 shares worth $606M.
- Jennison Associates added most to Charter Communications in Q4 2016, an estimated $601M increase.
- Jennison Associates's biggest Q4 2016 reduction was Biogen, cutting an estimated $733M.
- Jennison Associates fully exited lululemon athletica in Q4 2016, selling an estimated $342M.
- Jennison Associates's ten largest holdings make up 25% of its $89.6B portfolio in Q4 2016.
- Jennison Associates opened 208 new positions and closed 52 in Q4 2016.
- Jennison Associates's portfolio value fell 3.4% quarter-over-quarter to $89.6B.
Based on Jennison Associates's 13F filing for Q4 2016, filed 6 Feb 2017.